Stockreport

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment [Yahoo! Finance]

RenovoRx, Inc.  (RNXT) 
PDF Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for Drug-Delivery in Oncology Management MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE N [Read more]